Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
Fabian aus dem Siepen,1 Ralf Bauer,1 Matthias Aurich,1 Sebastian J Buss,1 Henning Steen,1 Klaus Altland,2 Hugo A Katus,1 Arnt V Kristen1 1Department of Cardiology, Angiology, and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2Institute of Human Genetics, Justus-Liebig-U...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-12-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/green-tea-extract-as-a-treatment-for-patients-with-wild-type-transthyr-peer-reviewed-article-DDDT |
id |
doaj-d65b527e6bbc4b60a0aa57b985262063 |
---|---|
record_format |
Article |
spelling |
doaj-d65b527e6bbc4b60a0aa57b9852620632020-11-24T23:48:27ZengDove Medical PressDrug Design, Development and Therapy1177-88812015-12-012015Issue 16319632524858Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational studyaus dem Siepen FBauer RAurich MBuss SJSteen HAltlKKatus HAKristen AVFabian aus dem Siepen,1 Ralf Bauer,1 Matthias Aurich,1 Sebastian J Buss,1 Henning Steen,1 Klaus Altland,2 Hugo A Katus,1 Arnt V Kristen1 1Department of Cardiology, Angiology, and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2Institute of Human Genetics, Justus-Liebig-University, Giessen, Germany Background: Causative treatment of patients with wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is lacking. Recent reports indicate the potential use of epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, to inhibit amyloid fibril formation. We sought to investigate changes of cardiac function and morphology in patients with wtATTR-CM after consumption of green tea extract (GTE). Methods: Twenty-five male patients (71 [64; 80] years) with wtATTR-CM were submitted to clinical examination, echocardiography, cardiac magnetic resonance imaging (cMRI) (n=14), and laboratory testing before and after daily consumption of GTE capsules containing 600 mg epigallocatechin-3-gallate for at least 12 months. Results: A significant decrease of left ventricular (LV) myocardial mass by 6% (196 [100; 247] vs 180 [85; 237] g; P=0.03) by cMRI and total cholesterol by 8.4% (191 [118; 267] vs 173 [106; 287] mg/dL; P=0.006) was observed after a 1-year period of GTE consumption. LV ejection fraction by cMRI (53% [33%; 69%] vs 54% [28%; 71%]; P=0.75), LV wall thickness (17 [13; 21] vs 18 [14; 25] mm; P=0.1), and mitral annular plane systolic excursion (10 [5; 23] vs 8 [4; 13] mm; P=0.3) by echocardiography remained unchanged. Conclusion: This study supports LV mass stabilization in patients with wtATTR-CM consuming GTE potentially indicating amyloid fibril reduction. Keywords: wild-type ATTR, cardiomyopathy, polyphenol, EGCGhttps://www.dovepress.com/green-tea-extract-as-a-treatment-for-patients-with-wild-type-transthyr-peer-reviewed-article-DDDTwildtype-ATTRcardiomyopathypolyphenolEGCG |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
aus dem Siepen F Bauer R Aurich M Buss SJ Steen H Altl K Katus HA Kristen AV |
spellingShingle |
aus dem Siepen F Bauer R Aurich M Buss SJ Steen H Altl K Katus HA Kristen AV Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study Drug Design, Development and Therapy wildtype-ATTR cardiomyopathy polyphenol EGCG |
author_facet |
aus dem Siepen F Bauer R Aurich M Buss SJ Steen H Altl K Katus HA Kristen AV |
author_sort |
aus dem Siepen F |
title |
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study |
title_short |
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study |
title_full |
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study |
title_fullStr |
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study |
title_full_unstemmed |
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study |
title_sort |
green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2015-12-01 |
description |
Fabian aus dem Siepen,1 Ralf Bauer,1 Matthias Aurich,1 Sebastian J Buss,1 Henning Steen,1 Klaus Altland,2 Hugo A Katus,1 Arnt V Kristen1 1Department of Cardiology, Angiology, and Respiratory Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2Institute of Human Genetics, Justus-Liebig-University, Giessen, Germany Background: Causative treatment of patients with wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is lacking. Recent reports indicate the potential use of epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, to inhibit amyloid fibril formation. We sought to investigate changes of cardiac function and morphology in patients with wtATTR-CM after consumption of green tea extract (GTE). Methods: Twenty-five male patients (71 [64; 80] years) with wtATTR-CM were submitted to clinical examination, echocardiography, cardiac magnetic resonance imaging (cMRI) (n=14), and laboratory testing before and after daily consumption of GTE capsules containing 600 mg epigallocatechin-3-gallate for at least 12 months. Results: A significant decrease of left ventricular (LV) myocardial mass by 6% (196 [100; 247] vs 180 [85; 237] g; P=0.03) by cMRI and total cholesterol by 8.4% (191 [118; 267] vs 173 [106; 287] mg/dL; P=0.006) was observed after a 1-year period of GTE consumption. LV ejection fraction by cMRI (53% [33%; 69%] vs 54% [28%; 71%]; P=0.75), LV wall thickness (17 [13; 21] vs 18 [14; 25] mm; P=0.1), and mitral annular plane systolic excursion (10 [5; 23] vs 8 [4; 13] mm; P=0.3) by echocardiography remained unchanged. Conclusion: This study supports LV mass stabilization in patients with wtATTR-CM consuming GTE potentially indicating amyloid fibril reduction. Keywords: wild-type ATTR, cardiomyopathy, polyphenol, EGCG |
topic |
wildtype-ATTR cardiomyopathy polyphenol EGCG |
url |
https://www.dovepress.com/green-tea-extract-as-a-treatment-for-patients-with-wild-type-transthyr-peer-reviewed-article-DDDT |
work_keys_str_mv |
AT ausdemsiepenf greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT bauerr greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT aurichm greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT busssj greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT steenh greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT altl greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT k greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT katusha greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy AT kristenav greenteaextractasatreatmentforpatientswithwildtypetransthyretinamyloidosisanobservationalstudy |
_version_ |
1725486079361941504 |